Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

@article{Conti1996IrinotecanIA,
  title={Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.},
  author={J A Conti and Nancy E. Kemeny and Leonard Saltz and Yu-jie Huang and William P. Tong and Ting Chao Chou and Mo-yi Sun and Samantha Pulliam and Carmen Gonz{\'a}lez},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 3},
  pages={709-15}
}
PURPOSE To determine the response rate, survival, and toxicity of the new anticancer agent, irinotecan (CPT-11), in the treatment of metastatic colorectal cancer. PATIENTS AND METHODS Forty-one chemotherapy-naive patients with measurable metastatic colorectal cancer were treated with a 90-minute infusion of irinotecan 125 mg/m2 administered weekly for 4 weeks every 6 weeks. Pretreatment tumor biopsies to assess topoisomerase-I (Topo-I) activity were obtained from 11 patients. The… CONTINUE READING
102 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

Similar Papers

Loading similar papers…